Ann: Trading Halt, page-90

What we already know?

Zelira enters into a commercial agreement to develop products targeting symptoms associated with Peripheral Arterial Disease and Diabetic Neuropathies 22 July 2020 • Zelira and Cardiovascular Solutions of Central Mississippi (CVSCM) enter into a binding agreement to develop and commercialize products that target symptoms associated with Peripheral Arterial Disease and Diabetic Neuropathies • Zelira will grant an exclusive license to CVSCM to manufacture, sell and otherwise commercialize Zelira’s proprietary formulations in the USA • Zelira will receive an upfront licensing fee and royalties on any commercialized products • CVSCM will be responsible for all costs relating to the production, marketing, distribution and sale of the products in the USA • This transaction expands and complements Zelira’s strategic interests in cardiovascular indications while maintaining focus on the global launch of its proprietary Zenivol™ and HOPE™ products